Navigation Links
New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
Date:9/25/2007

- Study led by Albert Einstein College of Medicine researchers published in

major scientific journal -

CLINTON, N.J., Sept. 25 /PRNewswire/ -- Producing a state of "hibernation on demand" in mice by administering an experimental drug from Ikaria (an injectable formulation of the biological gas hydrogen sulfide) showed promise in a study designed to reduce damage from heart attacks. The study was published in the online edition of the Proceedings of the National Academy of Sciences.

The preclinical study, conducted by researchers at New York's Albert Einstein College of Medicine and the University of Alabama, was funded in part by Ikaria and examined whether hydrogen sulfide could prevent "reperfusion injury" -- caused when blood flow and oxygen supply to heart tissue plummet during a heart attack, then are abruptly restored when the heart attack is treated. This dramatic change in oxygen levels can be heavily damaging to the heart.

"Over the last few years, a number of reports have demonstrated the protective effects of hydrogen sulfide in various models of cardiovascular disease and inflammation," said Csaba Szabo, M.D., Ph.D., chief scientific officer of Ikaria and a study co-author. "This study can be considered a milestone not only because it defines the significant therapeutic potential of hydrogen sulfide during heart attacks, but also because it links these therapeutic effects to hydrogen sulfide-induced on-demand metabolic modulation, a new field of biological research championed by Ikaria."

The senior study author was David Lefer of Albert Einstein College of Medicine's department of pathology and the division of cardiology within Albert Einstein's department of medicine.

While hydrogen sulfide is more commonly known as a toxic gas when it occurs at high levels, it has demonstrated a biologically protective role when delivered in very low doses, Dr. Szabo said. Ikaria has submitted regulatory docu
'/>"/>

SOURCE Ikaria
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Showcasing continued leadership in the ... company that provides scientifically advanced, age-defying products, has ... Selling Association (DSA) by the DSA Board of ... period, the DSA confirmed that Nerium’s business practices ... the association: to ensure that direct sales consumers ...
(Date:4/28/2015)... 2015  DanDrit Biotech USA , ... for the treatment of colorectal cancer, is pleased to ... with GISCAD Foundation, a highly recognized Italian group with ... The collaboration relates to VIVA, a Phase III adjuvant ... of disease (NED) Stage IV colorectal cancer (CRC). The ...
(Date:4/28/2015)... 2015  US-Australian drug discovery company, Novogen Limited (ASX: ... a letter from NASDAQ informing it that it had ... Rule). In November 2014, the Company ... to submit a plan to regain compliance with the ... $2,500,000 in stockholders, equity as of June 30, 2014; ...
(Date:4/28/2015)... Calverton, Maryland (PRWEB) April 28, 2015 ... Data Warehouse that bring it to the web ... visualization features and user friendly reporting metrics increase ... save reports for convenient recall and access “on-the-go” ... Warehouse was built using client feedback to assist ...
Breaking Biology Technology:Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 2DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 4Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3
... ,, BEIJING, China , May ... or the "Company") a leading developer,manufacturer, and distributor of Shengmingsu brand ... ("PRC"), today announced its,financial results for the quarter ended ... 2010 Highlights, -- Revenue increased 100.5% to $24.9 ...
... RESEARCH TRIANGLE PARK, N.C. , May 12 The International ... Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES ... early breast cancer and a median follow-up period of 91 months. ... from multiple centers. , , ...
... schedule , , , ... , , ... announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a ... of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2Resverlogix Completes Dosing for ASSERT Trial 2Resverlogix Completes Dosing for ASSERT Trial 3Resverlogix Completes Dosing for ASSERT Trial 4Resverlogix Completes Dosing for ASSERT Trial 5
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . ... infants was investigated using the prominent ,Stanford Marshmallow Experiment,: the children ... eat it now or wait and receive a second one if ... several minutes. Interestingly, children that were able to wait for the ...
... March 13, 2013, Shenzhen, China - In a collaborative study ... Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, ... of wild rice Oryza brachyantha . This work provides ... of Oryza genomes. The genus Oryza ...
... up and walked on two legs is considered to be one ... gone to the far ends of the earth and the ... we walk the way we walk. In the latest such ... Africa) have taken a closer look at bipedal kangaroos and wallabies ...
Cached Biology News:Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2It's all in the way we move 2